Myeloma 13-064

January 03, 2017

Sponsor: Memorial Sloan Kettering Cancer Center

Number: 13-064
Bortezomib, dexamethasone, and lenalidomide are drugs which are often given together to treat newly diagnosed multiple myeloma (a cancer of the bone marrow). However, this combination of three drugs is associated with significant side effects. Doctors may be able to achieve the same results using only two drugs and add the third drug only in patients who do not respond to the two-drug combination.

In this study, researchers will first give patients just two of the drugs (bortezomib and dexamethasone). Patients will only receive lenalidomide if their myeloma is not well controlled with bortezomib and dexamethasone alone. Doctors hope that giving the myeloma drugs in this way will be as effective as using all three drugs at the same time from the beginning, but with less side effects.

Who’s eligible: Patients must be newly diagnosed with symptomatic multiple myeloma and may not have received prior treatment. Patients must be able to be ambulatory for more than half of their normal waking hours.This study is open to patients age 18 and older.

Available at: Backus Hospital, MidState Medical Center, The Hospital of Central Connecticut, Hartford Hospital.